Ethan M. Shevach

Last updated
Ethan M. Shevach
Born1943
CitizenshipUnited States
Education Boston University Medical School (MD 1967)
Known for regulatory T cells
Awards William B. Coley Award (2004)
Scientific career
Fieldsimmunology
Institutions NIAID

Ethan Menahem Shevach (born 1943 [1] ) is an immunologist at the National Institute of Allergy and Infectious Diseases (NIAID) in Bethesda, Maryland.

Contents

Biography

Shevach obtained his M.D. from Boston University Medical School in 1967. After clinical training, he joined NIAID as a senior staff fellow in 1972 becoming head of a research group the following year and a departmental head (section chief) in 1987. As of 2018, he is head of the Department of Cellular Immunology at NIAID. [2]

Shevach served as editor-in-chief of the Journal of Immunology from 1987 to 1992 [3] and edited Cellular Immunology from 1996 to 2007. [2]

Research

Shevach made significant contributions towards understanding the function of regulatory T cells (TReg cells) in mediating the immune response. He discovered a subset of CD4+ T cells that express the transcription factor FOXP3 and operate by a mechanism that is distinct from the cytokine cascade. [4] Known as TReg cells, their primary function is immunosuppressive. [2] These TReg cells are targets for therapies against autoimmune diseases, cancer, and transplanted tissue rejection. [5]

Awards

He has been a member of the American Association of Immunologists since 1973 and received its Distinguished Service Award in 1992. [3]

In 2004, together with Shimon Sakaguchi, he won the Cancer Research Institute's William B. Coley Award for Distinguished Research in Basic and Tumor Immunology for his part in elucidating the function of regulatory T cells in the control of autoimmune diseases. [4]

Since 2015, Thomson Reuters (now Clarivate) has listed Shevach as among those most likely to win a Nobel Prize, based on his citation record. [6]

Related Research Articles

Polly Matzinger American immunologist

Polly Celine Eveline Matzinger is an immunologist who proposed the danger model theory of how the immune system works. In 2002, Discover magazine recognized Matzinger as one of the 50 most important women in science.

The National Institute of Allergy and Infectious Diseases is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

The regulatory T cells (Tregs or Treg cells), formerly known as suppressor T cells, are a subpopulation of T cells that modulate the immune system, maintain tolerance to self-antigens, and prevent autoimmune disease. Treg cells are immunosuppressive and generally suppress or downregulate induction and proliferation of effector T cells. Treg cells express the biomarkers CD4, FOXP3, and CD25 and are thought to be derived from the same lineage as naïve CD4+ cells. Because effector T cells also express CD4 and CD25, Treg cells are very difficult to effectively discern from effector CD4+, making them difficult to study. Research has found that the cytokine transforming growth factor beta (TGF-β) is essential for Treg cells to differentiate from naïve CD4+ cells and is important in maintaining Treg cell homeostasis.

FOXP3 Immune response protein

FOXP3, also known as scurfin, is a protein involved in immune system responses. A member of the FOX protein family, FOXP3 appears to function as a master regulator of the regulatory pathway in the development and function of regulatory T cells. Regulatory T cells generally turn the immune response down. In cancer, an excess of regulatory T cell activity can prevent the immune system from destroying cancer cells. In autoimmune disease, a deficiency of regulatory T cell activity can allow other autoimmune cells to attack the body's own tissues.

CTLA-4

CTLA-4 or CTLA4, also known as CD152, is a protein receptor that functions as an immune checkpoint and downregulates immune responses. CTLA-4 is constitutively expressed in regulatory T cells but only upregulated in conventional T cells after activation – a phenomenon which is particularly notable in cancers. It acts as an "off" switch when bound to CD80 or CD86 on the surface of antigen-presenting cells.

Ellen Heber-Katz

Ellen Heber-Katz is an American immunologist/regeneration biologist who is professor at Lankenau Institute for Medical Research (LIMR). She is an immunologist who investigates mammalian regeneration, having discovered the ability of the MRL mouse strain to regenerate wounds without scarring and to fully restore damaged tissues. Her work on regeneration has been extended into National Cancer Institute (NCI)-funded studies of novel aspects of breast cancer causation. Her research interests include immunology, regenerative medicine and cancer.

CD86

Cluster of Differentiation 86 is a protein constitutively expressed on dendritic cells, Langerhans cells, macrophages, B-cells, and on other antigen-presenting cells. Along with CD80, CD86 provides costimulatory signals necessary for T cell activation and survival. Depending on the ligand bound, CD86 can signal for self-regulation and cell-cell association, or for attenuation of regulation and cell-cell disassociation.

The William B. Coley Award for Distinguished Research in Basic and Tumor Immunology is presented annually by the Cancer Research Institute, to scientists who have made outstanding achievements in the fields of basic and tumor immunology and whose work has deepened our understanding of the immune system's response to disease, including cancer.

Interleukin 35 (IL-35) is a recently discovered anti-inflammatory cytokine from the IL-12 family. Member of IL-12 family - IL-35 is produced by wide range of regulatory lymphocytes and plays a role in immune suppression. IL-35 can block the development of Th1 and Th17 cells by limiting early T cell proliferation.

La Jolla Institute for Immunology

La Jolla Institute for Immunology is a non-profit research organization located in La Jolla, California. It is located in UC San Diego’s Research Park. The Institute researches immunology and immune system diseases. The Institute employs 220 M.D.s and Ph.D.s, including 23 faculty members and more than 450 employees. Dr. Mitchell Kronenberg has served as its president and scientific director since 2003. The institute was founded in 1988.

Vaccine Research Center

The Vaccine Research Center (VRC), is an intramural division of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), US Department of Health and Human Services (HHS). The mission of the VRC is to discover and develop both vaccines and antibody-based products that target infectious diseases.

Barton Ford Haynes is an American physician and immunologist internationally recognized for work in T-cell immunology, retrovirology and HIV vaccine development. Haynes is a Frederic M. Hanes Professor of Medicine and Immunology at Duke University Medical Center. He is the director of the Duke Human Vaccine Institute and the Duke Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID), which was funded by the National Institute of Allergy and Infectious Diseases (NIAID) in 2012. In addition, Haynes directs the B-cell Lineage Envelope Design Study, the Centralized Envelope Phase I Study, and the Role of IgA in HIV-1 Protection Study as part of the Collaboration for AIDS Vaccine Discovery (CAVD), which was funded by the Bill and Melinda Gates Foundation in 2006.

Donald W. Mason was a British immunologist and professor of immunology in the MRC Cellular Immunology Unit at the Sir William Dunn School of Pathology at the University of Oxford. Professor Mason is best known for his work on regulatory T cells and their role in preventing autoimmunity. His distinction was recognised by his election in 2017 to honorary life membership of the British Society for Immunology.

Harvey Cantor American immunologist

Harvey Cantor is an American immunologist known for his studies of the development and immunological function of T lymphocytes. Cantor is currently the Baruj Benacerraf Professor of Microbiology & Immunobiology at the Harvard Medical School.

STAT3 GOF is a rare genetic disorder of the immune system. Signal transducer and activator of transcription 3 (STAT3) is a transcription factor which is encoded by the STAT3 gene in humans. Germline gain-of-function (GOF) mutations in the gene STAT3 causes this early-onset autoimmune disease characterized by lymphadenopathy, autoimmune cytopenias, multiorgan autoimmunity, infections, eczema, and short stature. Investigations conducted by Sarah E Flanagan and Mark Russell from the Institute of Biomedical and Clinical Science, University of Exeter Medical School, Emma Haapaniemi from the Institute of Biomedical and Clinical Science, University of Exeter Medical Schoolby, and Joshua Milner from the National Institute of Allergy and Infectious Disease, National Institutes of Health have described this condition in 19 patients.

William Erwin Paul was an American immunologist. He and Maureen Howard discovered interleukin 4, while an independent team led by Ellen Vitetta did the same in 1982. Paul worked on AIDS research for much of his career at the National Institutes of Health (NIH). He served as president of the American Association of Immunologists from 1986 to 1987.

Shimon Sakaguchi

Shimon Sakaguchi is an immunologist and a Distinguished Professor of Osaka University. He is best known for the discovery of regulatory T cells and to describe their role in the immune system. This discovery is used in the treatment of cancer and autoimmune diseases.

Fred Ramsdell

Frederick J. "Fred" Ramsdell is an American immunologist.

Romina Goldszmid Argentine-American biologist

Silvana Romina Goldszmid is an Argentine-American biologist researching tumor immunology. She is an NIH Stadtman Investigator at the National Cancer Institute.

Michael J. Lenardo

Dr. Michael J. Lenardo, is the Chief of the Molecular Development and Immune System Section and the founder and co-Director of the Clinical Genomics Program at the National Institute of Allergy and Infectious Disease (NIAID), National Institutes of Health (NIH). Trained as a geneticist, molecular biologist, and immunologist, his research examines how cells of the immune system defend themselves against various pathogens, including viruses and bacteria. His research has investigated genetic abnormalities in the immune system, mechanisms of cell death, genetic diseases of immune homeostasis and autoimmunity, and development of novel diagnostics and therapeutics for diseases of the immune system. Lenardo's contributions to science and medicine have shown the possibilities of genomic research in developing precision medicine diagnoses and treatments for disease in humans. In 2006 he was appointed Officer of the Most Excellent Order of the British Empire (O.B.E.) by Queen Elizabeth II. In 2019 he was inducted into the National Academies of Sciences and the National Academy of Medicine, considered among the highest honors awarded to a U.S scientist and medical researcher respectively.

References

  1. "ISNI 0000000081982771 Ethan M. Shevach (1943-)". ISNI. Retrieved 16 October 2018.
  2. 1 2 3 "Ethan Shevach, M.D." NIH: National Institute of Allergy and Infectious Diseases. 18 November 2016. Retrieved 16 October 2018.
  3. 1 2 "Ethan M. Shevach". The American Association of Immunologists. 16 December 2015. Retrieved 16 October 2018.
  4. 1 2 "William B. Coley Award". Cancer Research Institute. Retrieved 16 October 2018.
  5. Miyara, Makoto; Gorochov, Guy; Ehrenstein, Michael; Musset, Lucile; Sakaguchi, Shimon; Amoura, Zahir (2011). "Human FoxP3+ regulatory T cells in systemic autoimmune diseases". Autoimmunity Reviews. 10 (12): 744–755. doi:10.1016/j.autrev.2011.05.004. ISSN   1568-9972. PMID   21621000.
  6. "2015 Citation Laureates Infographic". sciencewatch.com. 1 October 2015. Archived from the original on 1 October 2015. Retrieved 16 October 2018.